This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Spero Therapeutics’s 8K filing here.
Spero Therapeutics Company Profile
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Featured Stories
- Five stocks we like better than Spero Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- What is a Special Dividend?
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
